Merz Pharms Patent-Cliff Exposure & CMS Drug Spending Portfolio

Merz Pharms (US): 1 reconciled FDA prescription therapies, $11.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$11.7M
2024 Medicare Part D Spend$3.6M
2024 Medicaid Spend$8.1M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel